GlaxoSmithKline Pharmaceuticals Limited — PPTs, 14-02-2025: Investor Presentation

**Financial Highlights:** GSK posted a revenue of ₹946cr for Q3 FY25, reflecting an 18% growth year-over-year, with a PAT before exceptional items of ₹229cr, up 37%. The EBITDA stood at ₹290cr, representing a 33% growth and an impressive margin of 30.7%. Year-to-date (YTD), revenue reached ₹2757cr, a 10% increase, and PAT rose by 31% to ₹655cr, maintaining a margin of 24%. The improved margins are attributed to stronger performance across key brands and operational efficiencies.

**Strategic Initiatives and Growth Drivers:** The company’s strategy emphasizes the growth of its general medicine flagship brands and pediatric vaccines, with robust performances seen in Augmentin and Boostrix. Shingrix is also gaining traction through enhanced consumer awareness and creation of an adult vaccination ecosystem.

**Business Developments:** GSK celebrated its centenary in India with a notable event, including a customized stamp release, reinforcing its brand heritage and commitment to the country.

**Market Position and Competitive Advantage:** GSK continues to solidify its market position with a growing specialty portfolio and improving access, outpacing competitors in various segments.

**Investor Implications:** With an upward trajectory in revenue and profitability, GSK demonstrates a positive outlook. The focus on driving initiatives in vaccination and digital transformations positions the company favorably for future growth, making it a potential investment opportunity.